Cyclobenzaprine relieves skeletal muscle spasm of local origin without interfering with muscle function. Cyclobenzaprine has not been shown to be effective in muscle spasm due to central nervous system disease.

Cyclobenzaprine hydrochloride extended-release capsules are a muscle relaxant indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, and limitation of motion.

Recommended adult dose for most patients is 15 mg taken once daily. Some patients may require 30 mg taken once daily

Most common adverse reactions (incidence ≥3% in any treatment group and greater than placebo): dry mouth, dizziness, fatigue, constipation, nausea, dyspepsia, and somnolence.

• Hypersensitivity to any component of this product
• Concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation
• During acute recovery phase of myocardial infarction, and in patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure
• Hyperthyroidism

• Serotonin syndrome has been reported with cyclobenzaprine when used in combination with other serotonergic drugs (5.1)
• Cyclobenzaprine is structurally related to tricyclic antidepressants which have been reported to produce adverse cardiovascular effects or CNS depressant effects (5.2)
• Use in the elderly is not recommended (5.3)
• Use in patients with hepatic impairment is not recommended (5.4)
• Use with caution in patients with a history of urinary retention, angle-closure glaucoma, increased intraocular pressure and in patients taking anticholinergic medications (5.5)